[Form 4] GeoVax Labs, Inc. Warrants Insider Trading Activity

Rhea-AI Filing Summary

GeoVax Labs, Inc. reporting person Kelly T. McKee Jr., listed as Chief Medical Officer, reported a purchase of 1,107 shares of common stock on 08/07/2025 at $0.67 per share. The Form 4 shows transaction code P and reports 3,494 shares beneficially owned following the transaction; no derivative securities are listed.

Positive

• Insider purchase: Reporting person acquired 1,107 common shares
• Increased direct ownership: Beneficial ownership reported as 3,494 shares following the transaction

Negative

• None.

Insights

Securities Analyst

Insider purchase is modest and appears non-material to valuation; increases direct holdings slightly.

The Form 4 documents a small insider acquisition of 1,107 common shares at $0.67 each, bringing direct beneficial ownership to 3,494 shares. For most investors this size of purchase is informational but not material to company valuation. No derivative instruments were reported, and the transaction is coded P, suggesting it was a planned purchase as indicated on the form.

Corporate Governance Expert

Routine Form 4 disclosure showing compliance; governance implications are minimal.

The filing identifies Kelly T. McKee Jr. as an officer (Chief Medical Officer) and reports a direct purchase that increases his stake to 3,494 shares. The absence of derivative transactions and the presence of transaction code P indicate a straightforward insider purchase event with routine disclosure. This filing demonstrates compliance with Section 16 reporting obligations and does not reflect a governance concern.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKee Kelly T. Jr.

(Last) (First) (Middle)

C/O GEOVAX LABS, INC.

1900 LAKE PARK DR, SUITE 380

(Street)

SMYRNA GA 30080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GeoVax Labs, Inc. [ GOVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2025		P		1,107	A	$0.67	3,494	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Kelly T. McKee	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Kelly T. McKee Jr. report on Form 4 for GOVXW?

He reported acquiring 1,107 shares of GeoVax common stock on 08/07/2025.

At what price were the shares purchased in the GOVXW Form 4?

The shares were reported purchased at $0.67 per share.

How many GeoVax (GOVXW) shares does Kelly T. McKee Jr. beneficially own after the reported transaction?

The Form 4 reports 3,494 shares beneficially owned following the transaction (direct ownership).

What is Kelly T. McKee Jr.'s role at GeoVax listed on the Form 4?

He is listed as an Officer, specifically the Chief Medical Officer.

Were any derivative securities reported in the GeoVax Form 4?

No. Table II shows no derivative securities were acquired, disposed of, or beneficially owned.